64Cu-SAR-bisPSMA: FDA status

Breakthrough designation Indication: PSMA positive prostate cancer with suspected biochemical recurrence, PET imaging. Company: Clarity Pharmaceuticals.

Regulatory history

All products in the FDA Tracker

Loading today's edition…